# NB PRIVATE EQUITY PARTNERS STIFEL PRIVATE EQUITY SEMINAR

# INVESTOR OVERVIEW

22 MARCH 2016
FINANCIAL INFORMATION AS OF 29 FEBRUARY 2016 UNLESS OTHERWISE NOTED

# NB PRIVATE EQUITY PARTNERS ("NBPE")

### **OBJECTIVE**

To provide investors the opportunity for capital appreciation and current income

### **STRATEGY**

Invest directly into private equity-backed companies
Invest across the capital structure in the best relative
value opportunities

### **IMPLEMENTATION**

Using the sourcing and due diligence capabilities of Neuberger Berman's \$35 billion<sup>1</sup> private equity platform

### **EFFICIENCY**

Lower all-in costs to investors than other listed PE vehicles

<sup>1.</sup> Since inception through January 2016. Represents commitments managed and commitments still in the process of documentation.

# NB PRIVATE EQUITY PARTNERS

### NBPE invests in private equity backed companies

### **KEY HIGHLIGHTS**

Listing Date: 2007

• Market Capitalisation: \$507.5m

Net Asset Value (NAV): \$682.0m

• **NAV per Share:** \$13.98


Current share price: \$10.40

Dividend Yield on Share Price: 5.0%

 Investors have option to reinvest dividend or to receive dividend in sterling

NBPE has demonstrated a history of consistent strong investment performance

### **INVESTMENT TYPE** (by fair value)



# NEUBERGER BERMAN INVESTMENT PLATFORM

We invest directly into companies alongside private equity funds in their core areas of expertise

### PRIVATE EQUITY INVESTMENT APPROACH

- 55 senior investment professionals averaging 21 years of experience
- Active, "hands-on" approach to investment selection
- Opportunistic investors: Invest across the capital structure in new transactions or into existing portfolio companies of lead PE firms
- Proven, experienced and deep pool of resources
- Strong access to information and additional resources
- Preferred investment terms; low fee total







# NBPE TARGETED SECURITIES

NBPE invests directly into private equity backed companies

# REVOLVER FIRST LIEN TERM LOAN SECOND LIEN TERM LOAN OR MEZZANINE EQUITY

### **NBPE Target Securities**


- NBPE targets securities which offer the most attractive risk adjusted return
  - Junior debt can provide attractive yields
     on a risk-adjusted basis and is senior to
     equity in the capital structure
  - Equity provides the opportunity for capital gains
- All investment opportunities are subject to similar rigorous due diligence by our specialised teams

# DIVERSIFICATION

### Tactically overweighted to North America; diversified across industries


### **GEOGRAPHY**

(% of Fair Value)



### **INDUSTRY**


(% of Fair Value)



# GLOBAL PRIVATE EQUITY LP CASH FLOWS

Distributions have significantly outpaced capital calls since 2013


### TOTAL PRIVATE EQUITY MARKET CAPITAL CALLS VS. DISTRIBUTIONS



# PRIVATE EQUITY BUYOUT MULTIPLES

Purchase multiples have been steadily increasing in buyout deals since the financial crisis

### PUBLIC MARKET VS. PRIVATE MARKET VALUATIONS




Source: S&P Leveraged Buyout Quarterly Review as of Q4 2015. Public multiples based on Russell 2000 for the US and MSCI Europe Small Cap for Europe.

## PRIVATE EQUITY BUYOUT LEVERAGE

Leverage levels have been increasing in buyout deals since the financial crisis, but remain below the 2007 peak

AVERAGE LBO PRO FORMA CREDIT STATISTICS: TOTAL DEBT / EBITDA



# NBPE EQUITY INVESTMENT PORTFOLIO

NBPE has a well diversified direct equity portfolio, giving access to growing companies alongside high quality private equity sponsors

### NBPE EQUITY CO-INVESTMENTS

75 EQUITY CO-INVESTMENTS WITH \$324.1

MILLION OF FAIR VALUE **DIVERSIFIED** 

ACROSS VINTAGE YEARS,

**GEOGRAPHIES AND INDUSTRIES** 

**Valuations** 

Leverage

Growth

2015 Results<sup>3</sup>

10.3x EV / EBITDA VALUATION MULTIPLE<sup>1</sup> vs.

**15.1x** RUSSELL 2000<sup>2</sup>

4.7x NET DEBT / EBITDA1

3% LTM REVENUE GROWTH<sup>1</sup>
15% LTM EBITDA GROWTH<sup>1</sup>

8 EXITS GENERATING
1.9x GROSS MULTIPLE AND

25% GROSS IRR

Note: As of 29 February 2016.

<sup>1.</sup> Based on fair value as of 31 December 2015. Based on traditional buyout investments valued on a multiple of EBITDA, which represent 55% of direct equity investment fair value and excludes public companies and companies which were not valued on EV/EBITDA metrics and instead were valued based on multiples of revenue, book value, financing round, discounted cash flow or other metrics. Based on most recently available portfolio company information (unaudited).

Source: Bloombera.

<sup>3.</sup> Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns)

# NBPE DIRECT INCOME INVESTMENTS

The NBPE income portfolio is well diversified, performing well and has a reasonable average level of total leverage in the capital structure

### NBPE INCOME INVESTMENTS

- 43 income investments totaling \$286.0 million of fair value
  - 94% are in asset light companies
  - 68% are in a market leading position<sup>2</sup>
  - 55% are in companies with a >40% equity cushion
  - 58% are in companies with a >25% EBITDA margin
  - 100% are in performing credits with no covenant

issues

Strong Cash Yield<sup>1</sup>

9.8% CASH YIELD &
10.2% EST. YIELD TO MATURITY

Position in Capital Structure

5.3x WTD. AVG.
TOTAL DEBT / EBITDA
4.0x WTD. AVG.
SENIOR DEBT/ EBITDA

Variable Rates with Fixed Floor

**83%** OF FAIR VALUE IN FLOATING RATE DEBT

Supports NBPE Dividend

105% DIVIDEND COVERAGE


Note: As of 29 February 2016. Debt statistics exclude healthcare credit investments and small business loan portfolios.

<sup>1.</sup> Capital structure excludes small business loan programs and healthcare credit investments. Small business loan programs are excluded from yield calculations but are at an interest rate at least at the rate stated above.

<sup>2.</sup> Companies have a leading market position in their industry or niche based on NB's due diligence.

# DIVIDENDS AND CAPITAL POSITION

Dividend is fully covered by run rate cash yield from the income portfolio



Note: See endnote #3 for important information related to the dividend. Total yield (inclusive of PIK interest) represents the return (IRR) from this reporting period to the maturity of the investment. As of 29 February 2016.

<sup>1.</sup> Dividend coverage is gross of fees, expenses and financing costs.

<sup>2.</sup> Based on the company's most recent dividend and the NYSE Euronext closing share price of \$10.06 on 29 February 2016 and the 29 February 2016 monthly NAV of \$13.98 per share.

Unfunded commitments are adjusted by funds past their investment period and amounts which NBPE has the right to terminate if it so chooses.

# ATTRACTIVE VALUE PROPOSITION

We believe NBPE offers a compelling investment opportunity

- Capital appreciation and growth from equity investments
- Income through an attractive covered dividend, supported by the cash yield from the income portfolio
- **✓** Strong capital structure and commitment coverage
- Private equity exposure with attractive fee structure lower all-in fees than investing directly into LP funds



# NBPE NAV UPDATE

89% of NAV invested in direct investments and NAV per Share of \$13.98

### **NBPE SUMMARY BALANCE SHEET**

	29 February 2016	31 December 2015
(\$ in millions, except per share values)	(Unaudited)	(Audited)
Direct Investments		
Income Investments	\$286.0	\$283.0
Equity Investments	324.1	350.5
Total Direct Investments	610.1	633.5
Legacy Fund Investments	171.8	180.1
Total Private Equity Fair Value	781.8	813.6
Private Equity Investment Level	115%	116%
Cash and Cash Equivalents	35.7	26.1
Credit Facility Borrowings	(47.5)	(52.5)
ZDP Share Liability, including Forward Currency Contract	(80.2)	(74.7)
Net Other Assets (Liabilities), including Minority Interest	(7.8)	(12.1)
Net Asset Value	682.0	700.3
Net Asset Value Including Cumulative Dividends	759.6	765.7
Net Asset Value per Share	\$13.98	\$14.35
Cumulative Dividends per Share	\$1.59	\$1.34
Net Asset Value per Share Including Cumulative Dividends	\$15.57	\$15.69

Note: As of 29 February 2016.

# **EQUITY INVESTMENTS**

Company Name	Asset Class	Investment Date	Lead Sponsor	Fair Value	% of NBPE NAV
Acteon	Large-cap Buyout	Dec-12	KKR	\$1.6	0.2%
Nex & Ani	Mid-cap Buyout	May-15	Lion Capital	5.8	0.9%
American Dental Partners, Inc.	Mid-cap Buyout	Feb-12	JLL Partners	4.5	0.7%
Aster / DM Healthcare	Mid-cap Buyout	Jun-14	Olympus Capital	5.2	0.8%
Avaya	Large-cap Buyout	Oct-07	TPG / Silver Lake Partners	1.1	0.2%
Berlin Packaging	Mid-cap Buyout	Oct-14	Oak Hill Capital Partners	5.3	0.8%
Biotherapeutics Company B - Equity*	Special Situations	Jun-14	Not Disclosed	0.9	0.1%
Black Knight Financial Services	Large-cap Buyout	Dec-13	Thomas H. Lee	10.6	1.5%
Boa Vista	Mid-cap Buyout	Nov-12	TMG Capital	1.3	0.2%
Brickman Group	Large-cap Buyout	Dec-13	KKR	7.0	1.0%
Capsugel	Large-cap Buyout	Jul-11	KKR	8.7	1.3%
Centro	Growth / Venture	Jun-15	FTV Capital	3.1	0.5%
CoAdvantage	Mid-cap Buyout	Feb-13	Compass Investment Partners	0.1	0.0%
Connector Company*	Growth / Venture	Oct-15	Not Disclosed	4.0	0.6%
CommScope	Large-cap Buyout	Feb-11	Carlyle Group	2.9	0.4%
Compass Auto Group	Special Situations	Mar-14	Monomoy Capital	0.7	0.1%
Corona Industrials	Mid-cap Buyout	Jun-14	Victoria Capital	1.8	0.3%
Counsyl	Growth / Venture	Jul-14	Rosemont Seneca	5.8	0.8%
Consilio	Growth / Venture	Jul-15	Shamrock Capital	5.5	0.8%
SC Service Works	Large-cap Buyout	Mar-15	Pamplona Capital	5.8	0.8%
eltek (Equity)	Mid-cap Buyout	Dec-12	Carlyle Group	7.9	1.2%
ligital River (Equity)	Mid-cap Buyout	Feb-15	Siris Capital	8.7	1.3%
Illucian	Large-cap Buyout	Sep-15	TPG Capital	7.0	1.0%
vans Delivery Company (Equity)	Mid-cap Buyout	Jun-12	AEA Investors	8.7	1.3%
vogua Equity	Mid-cap Buyout	Jan-14	AEA Investors	3.2	0.5%
airmount Minerals	Mid-cap Buyout	Aug-10	American Securities Partners	0.6	0.1%
irst Data	Large-cap Buyout	Sep-07	KKR	2.6	0.4%
irth Rixson Equity	Mid-cap Buyout	Dec-07	Oak Hill Capital Partners	0.8	0.1%
ormation Energy	Mid-cap Buyout	Jul-13	Lindsay Goldberg	1.1	0.2%
reescale Semiconductor	Large-cap Buyout	Jul-07	Blackstone / Carlyle/ Permira / TPG	7.0	1.0%
Sabriel Brothers	Special Situations	Mar-12	A&M Capital	3.3	0.5%
Salco Industrials Equity	Special Situations	May-14	A&M Capital	0.8	0.1%
Sardner Denver, Inc.	Large-cap Buyout	Jul-13	KKR	6.5	1.0%
GC Services	Mid-cap Buyout	.lan-16	Owner Resource Group	4.4	0.0%
Genetic Testing Company - Equity*	Special Situations	Jun-13	Not Disclosed	9.6	1.4%
Group Ark Insurance	Mid-cap Buyout	Mar-07	Aquiline Capital Partners	0.7	0.1%
filsinger	Mid-cap Buyout	May-14	Blue Point Capital	4.5	0.1%
ncipio	Mid-cap Buyout	Feb-16	Goode Partners	1.5	0.7 %
novation Partners	Large-cap Buyout	Dec-15	Carlyle Group	1.9	0.2%
	<u> </u>	Oct-14		3.4	0.5%
nflection Energy nto University Partnerships	Mid-cap Buyout Mid-cap Buyout	Apr-13	Chambers Energy  Leeds Equity Partners	1.9	0.5%
· ·		Apr-13 Mar-11	TPG / Leonard Green	0.3	0.3%
.Crew Group (IK Custom Products (Equity)	Large-cap Buyout Mid-cap Buyout	Jan-00	CI Capital Partners	0.3	0.0%
( 1 2/		Jan-uu Dec-07		1.7	0.0%
Cyobo Life Insurance Co.	Mid-cap Buyout	Dec-07 Feb-15	Corsair Capital Partners		*.**
ookingglass	Growth / Venture		Alsop Louie	6.7	1.0%
Marquee Brands	Special Situations	Dec-14	Neuberger Berman	7.0	1.0%
MBI Energy	Mid-cap Buyout	Jun-14	Lindsay Goldberg	0.3	0.0%

Company Name	Asset Class	Investment Date	Lead Sponsor	Fair Value	% of NBPE NAV
Medical Diagnostics Company - Equity*	Special Situations	Jan-14	Not Disclosed	0.1	0.0%
Mills Fleet Farms	Large-cap Buyout	Feb-16	KKR	2.5	0.4%
Oil & Gas Company*	Mid-cap Buyout	May-14	Not Disclosed	18.3	2.7%
Oticas Carol	Growth / Venture	Apr-13	3i Brazil	2.1	0.3%
Ortholite Equity	Mid-cap Buyout	Apr-14	Blue Point Capital	6.5	1.0%
Patheon	Mid-cap Buyout	Mar-14	JLL Partners	16.6	2.4%
Petsmart	Large-cap Buyout	Jun-15	BC Partners	6.2	0.9%
Press Ganey Associates	Mid-cap Buyout	Mar-08	Vestar Capital	0.0	0.0%
ProMach	Mid-cap Buyout	Nov-14	AEA Investors	3.8	0.6%
Prosper	Growth / Venture	Apr-15	Multiple Sponsors	2.5	0.4%
RAC	Large-cap Buyout	Sep-11	Carlyle Group	4.5	0.7%
RevSpring	Mid-cap Buyout	Oct-12	Compass Investment Partners	1.9	0.3%
RiverBed	Mid-cap Buyout	Feb-15	Thoma Bravo	11.6	1.7%
Saguaro	Mid-cap Buyout	Jul-13	Pine Brook	9.8	1.4%
SBI Mortgage Co.	Mid-cap Buyout	Oct-14	Carlyle Group	5.2	0.8%
Seventh Generation	Growth / Venture	Apr-08	Catamount Ventures	1.8	0.3%
Shelf Drilling	Mid-cap Buyout	Feb-13	Castle Harlan Partners	2.9	0.4%
Skin Products Company - Equity*	Special Situations	Jul-13	Not Disclosed	2.4	0.4%
SolarWinds	Mid-cap Buyout	Feb-16	Thoma Bravo	3.5	0.5%
Specialty Drug Pharma. Company*	Mid-cap Buyout	Oct-15	Not Disclosed	0.5	0.1%
Specialty Drug Pharma. Company*	Special Situations	Nov-13	Not Disclosed	0.2	0.0%
Standard Aero	Mid-cap Buyout	Jun-15	Veritas Capital	5.7	0.8%
Stratus Technologies	Mid-cap Buyout	Apr-14	Siris Capital	2.7	0.4%
Swissport	Mid-cap Buyout	Feb-11	PAI	0.0	0.0%
Syniverse Technologies	Large-cap Buyout	Feb-11	Carlyle Group	3.0	0.4%
Taylor Precision Products	Mid-cap Buyout	Jul-12	Centre Partners	2.9	0.4%
Technology Company (Encryption App)*	Growth / Venture	Aug-14	Not Disclosed	1.5	0.2%
The Warranty Group	Large-cap Buyout	Jul-14	TPG	14.6	2.1%
TPF Genco	Mid-cap Buyout	Jul-07	Tenaska	0.9	0.1%
Univar	Large-cap Buyout	Nov-10	Clayton, Dublier & Rice	0.8	0.1%
Vencore (f/k/a The SI Organization)	Mid-cap Buyout	Nov-10	Veritas Capital	8.7	1.3%
Total Direct Equity Investment Portfolio				\$324.1	46.6%

Note: As of 29 February 2016.

<sup>\*</sup> Due to confidentiality provisions, company name cannot be disclosed.

# **INCOME INVESTMENTS**

INVESTMENT NAME	SECURITY DETAILS	INVESTMENT DATE	MATURITY DATE	FAIR VALUE <sup>1</sup>	CASH + PIK COUPON	CASH YIELD	TOTAL EST. YTM
Corporate Private Debt Investments							
2015							
Phillips Feed Service	Second lien (L+7.3% Cash, 1.0% L Floor; purchased @75)	Dec-15	Jan-22	\$3.6	8.3%	11.6%	13.2%
Total Fleet Solutions	Second lien (L+9.5% Cash, 1.0% L Floor)	Dec-15	Dec-20	7.1	10.5%	10.1%	10.0%
Syncsort	Second lien (L+8.5% Cash, 1.0% L Floor, 2% OID)	Nov-15	May-22	4.0	9.5%	9.6%	9.9%
Highbridge Loan Management	Loan portfolio	Oct-15	N/A	1.7	N/A	N/A	N/A
Linxens	Second lien (L+8.25% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	10.0	9.3%	9.3%	9.7%
Schumacher	Second lien (L+8.5% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	9.6	9.5%	9.6%	10.0%
Altegrity	First lien (9.5% Cash; purchased @ 94)	Sep-15	Jul-19	4.3	9.5%	11.0%	11.8%
Deltek - Re-finance	Second lien (L+8.50% Cash, 1.00% L Floor, 1% OID)	Jul-15	Jul-23	10.0	9.5%	9.4%	9.7%
Hyland	Second lien (L+7.25%, 1% Floor)	Jun-15	Jul-23	6.3	8.3%	8.2%	8.5%
MediMedia	Second lien (L+11% Cash, 1.25% L Floor; purchased @ 93)	Jun-15	Nov-19	10.2	12.3%	12.8%	12.7%
Physio Therapy Physio Therapy	Second lien (L+8.5%, 1% Floor)	Jun-15	Jun-22	2.5	9.5%	9.5%	9.7%
Catalina	Second lien (L+6.75%, 1% L Floor; purchased @78)	May-15	Apr-22	11.4	7.8%	12.9%	15.5%
Funding Circle	Portfolio of small business loans	Jan-15	N/A	16.0	N/A	N/A	N/A
Digital River Debt	First lien (L+5.75% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-21	1.8	6.8%	6.9%	6.7%
Digital River Debt	Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-22	4.0	12.0%	12.1%	12.6%
2014							
Compuware	Second lien (L+8.00% Cash, 1.0% L Floor, 8% OID)	Dec-14	Dec-22	14.2	9.0%	9.5%	9.2%
Central Security Group	Second lien (L+9.0% Cash, 1% L Floor, 5% OID)	Nov-14	Oct-21	5.9	10.0%	10.3%	10.3%
Vestcom	Second lien (L+8.0% Cash, 1.0% L Floor, 1.5% OID)	Oct-14	Sep-22	8.1	9.0%	9.0%	9.3%
K&N Engineering	Second lien (L+8.625%, 1% L Floor, 2.25% OID)	Jul-14	Jul-20	18.4	9.6%	9.6%	9.8%
Converge One	Second lien (L+8.0%, 1% L Floor, 1.0% OID)	Jun-14	Jun-21	20.1	9.0%	8.9%	9.2%
Authentic Brands	Second lien (L+8.0%, 1% L Floor, 1.0% OID)	Jun-14	May-22	13.0	9.0%	8.9%	9.2%
Galco Industrial Electronics	Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)	May-14	May-21	5.1	12.0%	10.4%	12.4%
Ortholite	Sr. sub notes (11.75% Cash, 1.5% OID)	Apr-14	Apr-20	15.1	11.8%	11.6%	12.0%
On Deck	Portfolio of small business loans	Apr-14	N/A	8.8	N/A	N/A	N/A
Flexera	Second lien (L+7.0%, 1% L Floor, 0.5% OID)	Apr-14	Apr-21	6.1	8.0%	7.9%	8.1%
LANDesk	Second lien (L+7.25%, 1% L Floor, 1% OID)	Mar-14	Feb-21	8.0	8.3%	8.3%	8.4%
Evoqua	Second lien (L+7.5%, 1% L Floor, 0.5% OID)	Jan-14	Jan-22	7.6	8.5%	8.4%	8.7%
2013							
Taylor Precision Products	Sr. sub notes (13% Cash, 1.5% OID)	Nov-13	May-19	5.9	13.0%	11.1%	9.3%
P2 Energy Solutions	Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)	Nov-13	May-21	5.0	9.0%	9.0%	9.3%
Heartland Dental	Second lien (L+8.5% Cash, 1.25% L Floor, 1.5% OID)	Jan-13	Jun-19	21.2	9.8%	9.6%	9.8%
Total Corporate Private Debt Investments Fair Value	· ,			\$265.2	9.6%	9.9%	10.2%

Note: As of 29 February 2016. Total yield (inclusive of PIK interest) represents the return (IRR) from this reporting period to the maturity of the investment.

1. See endnote #4 for important information on the income investment portfolio.

# INCOME INVESTMENTS (CON'T)

INVESTMENT NAME	SECURITY DETAILS	INVESTMENT DATE	MATURITY DATE	FAIR VALUE <sup>1</sup>	CASH + PIK COUPON	CASH YIELD	TOTAL EST. YTM
Total Healthcare Credit Investments							
2016							
Generic Pharmaceutical Company	Senior secured term loan (L + 5.375%, 1% Floor)	Jan-16	Nov-22	-	6.4%	6.8%	7.9%
2015							
Term Loan (Medical Implants)	Second lien (L+8.50%, 1% L Floor, 6% OID)	Mar-15	Dec-22	-	9.5%	10.7%	9.9%
Royalty Notes (Biotechnology)	Royalty backed note (9.375% Cash)	Mar-15	Mar-26	-	9.4%	9.0%	9.7%
2014							
Term Loan (Biotherapeutics B)	Convertible notes (4.5% Cash)	Jun-14	May-19	-	4.5%	3.5%	4.1%
Term Loan (Contract Research Organization)	Second lien (L+8.25%, 1% L Floor, 1% OID)	Apr-14	Mar-22	-	9.3%	9.8%	9.5%
Convertible Notes (Specialty Pharmaceuticals)	Convertible notes (4.5% Cash)	Apr-14	May-20	-	4.5%	6.9%	4.3%
Term Loan (Specialty PCP and Pediatric Pharmaceuticals)	Senior secured loan (first lien, 12% cash, 0.75% fee)	Feb-14	Feb-19	-	12.0%	11.4%	11.2%
Term Loan (Medical Diagnostics)	Senior secured loan (10.5% Cash)	Jan-14	Dec-18	-	10.5%	11.5%	11.1%
2013							
Term Loan (Skin Products Company)	Senior secured loan (First Lien, 10.5% Cash, 1.5% Fee)	Jul-13	Jul-18	-	10.5%	7.1%	10.4%
Term Loan (Genetic Testing)	Senior secured loan (First Lien, 10% Cash, 1% Fee)	Jun-13	Jun-18	-	10.0%	10.8%	9.8%
Term Loan (Cardiac Device)	Escrow value	Feb-13	Mar-18	-	-	-	-
Royalty Notes (Internal Medication)	Royalty backed note	Jan-13	Jun-24	-	11.0%	11.8%	11.9%
Royalty Notes (Hormone Therapy)	Royalty backed note	Apr-11	N/A	-	N/M	N/M	N/M
Total Healthcare Credit Investments Fair Value				\$20.8	9.4%	9.2%	9.6%
Total Income Portfolio Fair Value				\$286.0	9.2%	9.8%	10.1%

Note: As of 29 February 2016. Total yield (inclusive of PIK interest) represents the return (IRR) from this reporting period to the maturity of the investment. Due to confidentiality provisions, company names cannot be disclosed. Hormone Therapy royalty backed notes are N/M due to duration.

<sup>1.</sup> See endnote #4 for important information on the income investment portfolio.

# **FUND INVESTMENTS**

Investment Name	Asset Class	Vintage Year	Unfunded Commitment	Fair Value
Catalyst Fund III	Special Situations Funds	2011	\$2.3	\$15.8
NB Crossroads Fund XVIII - Mid-cap Buyout	Mid-cap Buyout Funds	Fund XVIII	7.1	15.5
NB Crossroads Fund XVII	Fund XVII (Diversified)	Fund XVII	1.9	14.3
Bertram Growth Capital II	Growth / Venture Funds	2010	2.4	10.9
OCM Principal Opportunities Fund IV	Mid-cap Buyout Funds	2007	2.0	10.4
NB Crossroads Fund XVIII - Venture Capital	Growth / Venture Funds	Fund XVIII	1.7	8.0
Sun Capital Partners V	Special Situations Funds	2007	1.3	7.6
Bertram Growth Capital I	Growth / Venture Funds	2007	1.2	7.3
Avista Capital Partners	Mid-cap Buyout Funds	2006	0.3	7.3
NG Capital Partners I , L.P.	Growth / Venture Funds	2010	0.1	7.2
Platinum Equity Capital Partners II	Special Situations Funds	2007	2.9	6.6
NB Crossroads Fund XVIII - Large-cap Buyout	Large-cap Buyout Funds	Fund XVIII	2.2	6.0
Corsair III Financial Services Capital Partners	Mid-cap Buyout Funds	2007	1.1	5.5
Sankaty Credit Opportunities III	Special Situations Funds	2007	0.0	5.2
Oaktree Opportunities Fund VIII	Special Situations Funds	2009	0.0	4.4
NB Crossroads Fund XVIII - Special Situations	Special Situations Funds	Fund XVIII	0.9	3.9
Lightyear Capital Fund II	Mid-cap Buyout Funds	2006	1.4	3.6
NB Fund of Funds Secondary 2009	Mid-cap Buyout Funds	2009	0.9	3.4
CVI Global Value Fund	Special Situations Funds	2006	0.8	3.1
Highstar Capital Fund II	Mid-cap Buyout Funds	2004	0.1	3.0
14 Other Fund Investments (< \$3m individually)			13.3	22.7
Total Fund Portfolio			\$43.8	\$171.8

# CREDIT FACILITY

### As of 29 February 2016, NBPE had \$47.5 million of borrowings drawn

TOTAL ASSET RATIO

Not to exceed 50%

SECURED ASSET RATIO

Not to exceed 80%

COMMITMENT RATIO

If total asset ratio >25% and commitment ratio is >130%. then NBPE is restricted from making new private equity investments

**Total Debt + Current Liabilities** 

Restricted NAV + Cash & Equivalents

(Restricted NAV is the value of private equity

investments less any excluded value)

**Total Debt + Current Liabilities** 

**Secured Assets** 

(Secured assets are the value of secured private equity investments plus cash and equivalents)

**Potential Total Exposure** 

Shareholder's Equity + Total Credit Facility

(Potential total exposure is the value of private equity investments plus unfunded private equity commitments)

Total Asset Ratio = 7.0%

**Secured Asset Ratio = 9.2%** 

**Commitment Ratio = 117.8%** 

- NBPE has a revolving credit facility with Lloyds Banking Group for up to \$200 million with a term expiring in April 2017
  - Borrowings under the credit facility bear interest at tiered rates based on loan value
    - LIBOR/EURIBOR plus 2.80% per annum for loan value less than or equal to \$65 million
    - LIBOR/EURIBOR plus 3.30% per annum for loan value in excess of \$65 million and less than or equal to \$150 million
    - LIBOR/EURIBOR plus 3.65% per annum for a loan value greater than \$150 million

Note: As of 29 February 2016.

# TRADING INFORMATION

Trading Symbol:	NBPE
Exchanges:	Euronext Amsterdam & London Stock Exchange
Base Currency:	USD
Bloomberg:	NBPE NA, NBPE LN
Reuters:	NBPE.AS, NBPE.L
ISIN:	GG00B1ZBD492
COMMON:	030991001

Trading Symbol:	NBPZ
Exchanges:	London Stock Exchange & The Channel Islands Securities Exchange Authority Limited
Base Currency:	GBP
Bloomberg:	NBPEGBP LN
Reuters:	NBPEO.L
ISIN:	GG00B4ZXGJ22
SEDOL:	B4ZXGJ2
Gross Redemption Yield:	7.30% at issuance
Share Life:	7.5 years to 31 May 2017
Final Capital Entitlement:	169.73 pence per share at maturity

# **CONTACT INFORMATION**

Registered Office:	NB Private Equity Partners Limited P.O. Box 225 Heritage Hall, Le Marchant Street St. Peter Port, Guernsey GY1 4HY Channel Islands Tel: +44.(0).1481.716.000
Investment Manager:	NB Alternatives Advisers LLC 325 N. Saint Paul Street Suite 4900 Dallas, TX 75201 United States of America
Investor Relations:	Web: www.nbprivateequitypartners.com Email: IR_NBPE@nb.com Tel: +1.214.647.9593
Media Relations:	Neustria Partners Nick Henderson Tel: +44.20.3021.2583

Corporate Brokers:	Stifel Nicolaus Neil Winward Tel: +44.20.7710.7600
	Jefferies International Limited Gary Gould/Stuart Klein Tel: +44.20.7029.8766
Research Analysts:	Stifel Nicolaus- Iain Scouller Email: iain.scouller@stifel.com
	Jefferies – Mark Ambrose, CFA Email: mambrose@jefferies.com
	J.P. Morgan Cazenove – Christopher Brown Email: christopher.brown@jpmorgan.com
	Canaccord Genuity – Alan Brierley Email: abrierley@canaccordgenuity.com
	Dexion – Tom Skinner Email: tom.skinner@dexioncapital.com
	Liberum Capital – Coner Finn Email: coner.finn@liberumcapital.com
	Numis – Charles Cade & Sarah Lewandowski Email: c.cade@numis.com
	Winterflood – Simon Elliott Email: simon.elliott@wins.co.uk

# **ENDNOTES**

- 1. The diversification analysis by asset class and investment type is based on the fair value of underlying fund investments and direct/co-investments. Determinations regarding asset class and investment type represent the Investment Manager's estimates. Accordingly, the actual diversification of our investment portfolio and the diversification of our investment portfolio and ongoing basis may vary from the foregoing information. For the NB Alternatives Direct Co-investment Program and the NB Healthcare Credit Investment Program commitments, total exposure only reflects the funded investments to date. Unfunded amounts and unfunded percentages within each of these programs are excluded from the analysis, as capital deployment is opportunistic and cannot be accurately forecast at this time.
- 2. The diversification analysis by geography is based on the diversification of underlying portfolio company investments at fair value as estimated by the Investment Manager. Determinations regarding geography and industry also represent the Investment Manager's estimates. Accordingly, the actual diversification of our investment portfolio and the diversification of our investment portfolio on an ongoing basis may vary from the foregoing information. For the NB Alternatives Direct Co-investment Program and the NB Healthcare Credit Investment Program commitments, total exposure only reflects the funded investments to date. Unfunded amounts and unfunded percentages within each of these programs are excluded from the analysis, as capital deployment is opportunistic and cannot be accurately forecast at this time.
- 3. Guidance regarding NBPE's future portfolio and performance is a target only and not a profit forecast. There can be no assurance that this target will be met or that the Company will make any future distributions whatsoever. Any such changes will be notified to shareholders through a regulatory information service. NBPE's Board of Directors will continue to evaluate the Company's financial position, annual dividend target and the timing of future dividends. Future dividend payments will be announced by NBPE after the Board of Directors have completed such evaluation.
- 4. Yield to maturities represent the return (IRR) from this reporting period to maturity of the investment. Includes a portfolio of small business loans at an interest rate at least at the rate stated above but not included in the yield calculations. The Taylor Precision Products debt notes currently pay 13% cash, but issuer has the option to pay 11% and 2% PIK.
- 5. Actual unfunded commitments are \$257.4 million at 29 February 2016, corresponding to actual over commitment of \$69.2 million and an actual commitment coverage ratio of 73%. Unfunded adjustments include removing unfunded commitments to funds past their investment period (although some amount may be called for future follow-ons or expenses), unfunded commitments to fund of funds managed by the Manager, amounts which can be terminated by the manager, and adjusting the unfunded commitment to one investment in the income category where the Manager does not expect capital drawn to exceed 40% of the original commitment due to daily paybacks. Commitment coverage and adjusted unfunded numbers may not be directly comparable to prior quarters due the exclusion of \$150 million committed to the next NB Alternatives Direct Co-investment Program.

# LEGAL DISCLAIMER

THE CONTENTS OF THIS DOCUMENT AND THE PRESENTATION ARE STRICTLY CONFIDENTIAL AND MAY NOT BE COPIED, DISTRIBUTED, PUBLISHED OR REPRODUCED IN WHOLE OR IN PART, OR DISCLOSED OR DISTRIBUTED BY RECIPIENTS TO ANY OTHER PERSON. ANY RECIPIENT OF THIS DOCUMENT AGREES TO KEEP PERMANENTLY CONFIDENTIAL ALL INFORMATION HEREIN NOT ALREADY IN THE PUBLIC DOMAIN.

This document and the presentation are not for release, publication or distribution (directly or indirectly) in or into the United States, Canada, Australia or Japan or to any "US person" as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act") or into any other jurisdiction where applicable laws prohibit its release, distribution or publication. It does not constitute an offer of securities for sale anywhere in the world, including in or into the United States, Canada, Australia or Japan. No recipient may distribute, or make available, this document or the presentation (directly or indirectly) to any other person. Recipients of this document and the presentation should inform themselves about and observe any applicable legal requirements in their jurisdictions. In particular, the distribution of this document and the presentation may in certain jurisdictions be restricted by law. Accordingly, recipients represent that they are able to receive this document and relating presentation without contravention of any applicable legal or regulatory restrictions in the jurisdiction in which they reside or conduct business.

This document and the presentation have been prepared by NB Private Equity Partners Limited ("NBPE") and NB Alternatives Advisers LLC (the "Investment Manager"). No member of the Neuberger Berman Group nor any of their respective directors, officers, employees, advisors, representatives, or other agents makes or has been authorised to make any representation or warranties (express or implied) in relation to NBPE or as to the truth, accuracy or completeness of this document or the presentation, or any other written or oral statement provided. In particular, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on any projections, targets, estimates or forecasts contained in this document or the presentation and nothing in this document or the presentation as to the future. The name "Neuberger Berman" is used interchangeably throughout these materials for a number of entities that are part of, or are associated with, the Neuberger Berman Group and when used in this notice includes all such entities.

This document does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of NBPE or other evaluation of any securities of NBPE or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities. Neither the issue of this document nor the presentation nor any part of their contents constitutes an offer to sell or invitation to purchase any securities of NBPE or any other entity or any persons holding securities of NBPE and no information set out in this document or the presentation or referred to in other written or oral information is intended to form the basis of any contract of sale, investment decision or any decision to purchase any securities referred to in it.

The information contained in this document is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment. No reliance may be placed for any purpose whatsoever on the information of opinions contained in this document or on its completeness, accuracy or fairness. The contents of this document have not been approved by any competent regulatory or supervisory authority.

This document, any presentation made in conjunction with this document and any accompanying materials (the "Information Materials") are made available for information purposes only. The Information Materials, which are not a prospectus or listing particulars or an admission document, do not contain any representations, do not constitute or form part of any offer or invitation to sell or transfer, or to underwrite, subscribe for or acquire, any shares or other securities, and do not constitute or form any part of any solicitation of any such offer or invitation, nor shall they are or any part of them or the fact of their distribution form the basis of or be relied upon in connection with any contract therefore, and do not constitute a recommendation regarding the securities of NBPE.

Neither NBPE nor Neuberger Berman gives any undertaking to provide the recipient with access to any additional information, or to update this document, the presentation or any additional information, or to correct any inaccuracies in it which may become apparent and the distribution of this document and the presentation shall not be deemed to be any form of commitment on the part of NBPE, the Investment Manager or Neuberger Berman to proceed with any transaction.

# LEGAL DISCLAIMER - CONTINUED

THE PROMOTION OF NBPE AND THE DISTRIBUTION OF THIS DOCUMENT AND THE PRESENTATION IN THE UNITED KINGDOM IS RESTRICTED BY LAW. ACCORDINGLY, THIS COMMUNICATION IS DIRECTED ONLY AT (I) PERSONS OUTSIDE THE UNITED KINGDOM TO WHOM IT IS LAWFUL TO COMMUNICATE TO, OR (II) PERSONS HAVING PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS WHO FALL WITHIN THE DEFINITION OF "INVESTMENT PROFESSIONALS" IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED), OR (III) HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS AND PARTNERSHIPS AND TRUSTEES OF HIGH VALUE TRUSTS AS DESCRIBED IN ARTICLE 49(2) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED); PROVIDED THAT IN THE CASE OF PERSONS FALLING INTO CATEGORIES (II) OR (III), THE COMMUNICATION IS ONLY DIRECTED AT PERSONS WHO ARE ALSO "QUALIFIED INVESTORS" AS DEFINED IN SECTION 86 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (EACH A "RELEVANT PERSON"). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS COMMUNICATION RELATES IS AVAILABLE ONLY TO AND WILL BE ENGAGED IN ONLY WITH SUCH RELEVANT PERSONS. PERSONS WITHIN THE UNITED KINGDOM WHO RECEIVE THIS COMMUNICATION (OTHER THAN PERSONS FALLING WITHIN (II) ABOVE) SHOULD NOT RELY ON OR ACT UPON THIS COMMUNICATION. YOU REPRESENT AND AGREE THAT YOU ARE A RELEVANT PERSON.

NBPE HAS NOT BEEN, AND HAS NO INTENTION TO BE, REGISTERED UNDER THE U.S. INVESTMENT COMPANY ACT OF 1940, AS AMENDED (THE "INVESTMENT COMPANY ACT") AND INVESTORS WILL NOT BE ENTITLED TO THE BENEFITS OF THAT ACT. THE SECURITIES DESCRIBED IN THIS DOCUMENT HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT. CONSEQUENTLY, SUCH SECURITIES AND YOUNGER THE SECURITIES ACT DINCHES SUCH SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENT OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF THE SECURITIES IS BEING MADE IN THE UNITED STATES.

PROSPECTIVE INVESTORS SHOULD TAKE NOTE THAT ANY SECURITIES MAY NOT BE ACQUIRED BY INVESTORS USING ASSETS OF ANY RETIREMENT PLAN OR PENSION PLAN THAT IS SUBJECT TO PART 4 OF SUBTITLE B OF TITLE I OF THE UNITED STATES EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED ("ERISA") OR SECTION 4975 OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"), ENTITIES WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE "PLAN ASSETS" OF ANY SUCH RETIREMENT PLAN OR PENSION PLAN, OR ANY GOVERNMENTAL PLAN, CHURCH PLAN, NON-U.S. PLAN OR OTHER INVESTOR SUBJECT TO ANY STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS SIMILAR TO TITLE I OR ERISA OR SECTION 4975 OF THE CODE OR THAT WOULD HAVE THE EFFECT OF THE REGULATIONS ISSUED BY THE UNITED STATES DEPARTMENT OF LABOR SET FORTH AT 29 CFR SECTION 2510.3-101, AS MODIFIED BY SECTION 3(42) OF ERISA.

THE MERITS OR SUITABILITY OF ANY SECURITIES MUST BE INDEPENDENTLY DETERMINED BY THE RECIPIENT ON THE BASIS OF ITS OWN INVESTIGATION AND EVALUATION OF NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN. ANY SUCH DETERMINATION SHOULD INVOLVE, AMONG OTHER THINGS, AN ASSESSMENT OF THE LEGAL, TAX, ACCOUNTING, REGULATORY, FINANCIAL, CREDIT AND OTHER RELATED ASPECTS OF THE SECURITIES. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION ARE RECOMMENDED TO SEEK THEIR OWN INDEPENDENT LEGAL, TAX, FINANCIAL AND OTHER ADVICE AND SHOULD RELY SOLELY ON THEIR OWN JUDGMENT, REVIEW AND ANALYSIS IN EVALUATING NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN, AND THEIR BUSINESS AND AFFAIRS.

THIS DOCUMENT AND THE PRESENTATION MAY CONTAIN CERTAIN FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS RELATE TO EXPECTATIONS, BELIEFS, PROJECTIONS, FUTURE PLANS AND STRATEGIES, ANTICIPATED EVENTS OR TRENDS AND SIMILAR EXPRESSIONS CONCERNING MATTERS THAT ARE NOT HISTORICAL FACTS. IN SOME CASES, FORWARD-LOOKING STATEMENTS CAN BE INDENTIFIED BY TERMS SUCH AS "ANTICIPATE", BELIEVE", "COULD", "ESTIMATE", "EXPECT", "INTEND", "MAY", "PLAN", "POTENTIAL", "SHOULD", "WILL", AND "WOULD", OR THE NEGATIVE OF THOSE TERMS OR OTHER COMPARABLE TERMINOLOGY. THE FORWARD-LOOKING STATEMENTS ARE BASED ON NBPE'S AND/OR NEUBERGER BERMAN'S BELIEFS, ASSUMPTIONS AND EXPECTATIONS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL INFORMATION CURRENTLY AVAILABLE. THESE BELIEFS, ASSUMPTIONS, AND EXPECTATIONS CAN CHANGE AS A RESULT OF MANY POSSIBLE EVENTS OR FACTORS, NOT ALL OF WHICH ARE KNOWN OR ARE WITHIN NBPE'S OR NEUBERGER BERMAN'S CONTROL. IF A CHANGE OCCURS, NBPE'S BUSINESS, FINANCIAL CONDITION, LIQUIDITY AND RESULTS OF OPERATIONS MAY VARY MATERIALLY FROM THOSE EXPRESSED IN FORWARD-LOOKING STATEMENTS. SOME OF THE FACTORS THAT COULD CAUSE ACTUAL RESULTS TO VARY FROM THOSE EXPRESSED IN FORWARD-LOOKING STATEMENTS, INCLUDE, BUT ARE NOT LIMITED TO: THE FACTORS DESCRIBED IN THIS DOCUMENT AND THE PRESENTATION; THE RATE AT WHICH NBPE DEPLOYS ITS CAPITAL IN INVESTMENTS AND ACHIEVES EXPECTED RATES OF RETURN; NBPE'S AND THE INVESTMENT MANAGER'S ABILITY TO EXECUTE NBPE'S INVESTMENT STRATEGY, INCLUDING THROUGH THE IDENTIFICATION OF A SUFFICIENT NUMBER OF APPROPRIATE INVESTMENTS; THE CONTINUATION OF THE INVESTMENT MANAGER AS MANAGER OF NBPE'S INVESTMENTS, THE CONTINUED AFFILIATION WITH NEUBERGER BERMAN OF ITS KEY INVESTMENT PROFESSIONALS; NBPE'S FINANCIAL CONDITIONS; AND THE GENERAL VOLATILITY OF THE CAPITAL MARKETS AND THE MARKET PRICE OF NBPE'S SHARES.

BY THEIR NATURE, FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES BECAUSE THEY RELATE TO EVENTS, AND DEPEND ON CIRCUMSTANCES THAT MAY OR MAY NOT OCCUR IN THE FUTURE. FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE. ANY FORWARD-LOOKING STATEMENTS ARE ONLY MADE AS AT THE DATE OF THIS DOCUMENT AND THE PRESENTATION, AND NEITHER NBPE NOR THE INVESTMENT MANAGER ASSUMES ANY OBLIGATION TO UPDATE FORWARD-LOOKING STATEMENTS SET FORTH IN THIS DOCUMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS, OR OTHERWISE, EXCEPT AS REQUIRED BY LAW OR OTHER APPLICABLE REGULATION. IN LIGHT OF THEIR RISKS, UNCERTAINTIES, AND ASSUMPTIONS, THE EVENTS DESCRIBED BY ANY SUCH FORWARD-LOOKING STATEMENTS BY THESE CAUTIONARY FACTORS. PLEASE KEEP THIS CAUTIONARY NOTE IN MIND WHILE READING THIS DOCUMENT.

# LEGAL DISCLAIMER - CONTINUED

BY ACCEPTING AND READING THIS DOCUMENT AND/OR ATTENDING THE PRESENTATION TO WHICH THIS DOCUMENT RELATES YOU WILL BE DEEMED TO HAVE REPRESENTED, WARRANTED AND UNDERTAKEN FOR THE BENEFIT OF NBPE, THE INVESTMENT MANAGER, NEUBERGER BERMAN AND OTHERS THAT (A) YOU ARE OUTSIDE OF THE UNITED STATES AND ARE AN "INVESTMENT PROFESSIONAL" (AS DEFINED ABOVE), (B) YOU HAVE READ AND AGREE TO COMPLY WITH THE CONTENTS OF THIS NOTICE, YOU WILL KEEP THE INFORMATION IN THIS DOCUMENT AND DELIVERED DURING ANY PRESENTATION OR CONTAINTED IN ANY ACCOMPANYING DOCUMENT AND ALL INFORMATION ABOUT NEUBERGER BERMAN CONFIDENTIAL, AND WILL NOT REPRODUCE OR DISTRIBUTE, IN WHOLE OR IN PART, (DIRECTLY OR INDIRECTLY) ANY SUCH INFORMATION, UNTIL SUCH INFORMATION HAS BEEN MADE PUBLICLY AVAILABLE AND TAKE ALL REASONABLE STEPS TO PRESERVE SUCH CONFIDENTIALITY, AND (C) YOU ARE PERMITTED, IN ACCORDANCE WITH APPLICABLE LAWS, TO RECEIVE SUCH INFORMATION.

NBPE IS ESTABLISHED AS A CLOSED-END INVESTMENT COMPANY IN GUERNSEY AND THE COMPANY IS SUBJECT TO THE NETHERLANDS FINANCIAL SUPERVISION ACT (WET OP HET FINANCIEEL TOEZICHT, "WFT"), AS A LISTED ENTITY (UITGEVENDE INSTELLING) AS DEFINED IN SECTION 1:1 OF THE WFT. ALL INVESTMENTS ARE SUBJECT TO RISK. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RETURNS. PROSPECTIVE INVESTORS ARE ADVISED TO SEEK EXPERT LEGAL, FINANCIAL, TAX AND OTHER PROFESSIONAL ADVICE BEFORE MAKING ANY INVESTMENT DECISION. THE VALUE OF INVESTMENTS MAY FLUCTUATE. RESULTS ACHIEVED IN THE PAST ARE NO GUARANTEE OF FUTURE RESULTS.

THIS DOCUMENT IS ISSUED BY NBPE WHOSE REGISTERED ADDRESS IS AT HERITAGE HALL, PO BOX 225, LE MARCHANT STREET, ST. PETER PORT, GUERNSEY GY1 4HY. NB ALTERNATIVES ADVISERS LLC IS A REGISTERED INVESTMENT ADVISER IN THE UNITED STATES. NEUBERGER BERMAN IS A REGISTERED TRADEMARK. ALL RIGHTS RESERVED. ©2016 NB ALTERNATIVES ADVISERS LLC.